Reduces blood pressure Producing controlled hypotension. ANDA 215846, held by Hainan Poly. Sodium Nitroprusside.
As of Nov 16, 2026, ANDA 215846 (Sodium Nitroprusside), held by Hainan Poly, was first approved by FDA on Aug 26, 2022, with 0 approved supplements and 0 published complete response letters.
Sodium nitroprusside is a direct acting vasodilator indicated for: Immediate reduction of blood pressure Producing controlled hypotension to reduce bleeding during surgery Treatment of acute heart failure to reduce left ventricular end-diastolic pressure, pulmonary capillary wedge pressure, peripheral vascular resistance and mean arterial blood pressure 1.1 Immediate Reduction of Blood Pressure Sodium nitroprusside is indicated for the immediate reduction of blood pressure of adult and pediatric patients in hypertensive crises. 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 26, 2022 | Original application | Approved |
| Sodium Nitroprusside10MG/50ML (0.2MG/ML) · solution;intravenous | Sodium Nitroprusside | Rx |
| Sodium Nitroprusside20MG/100ML (0.2MG/ML) · solution;intravenous | Sodium Nitroprusside | Rx |
| Sodium Nitroprusside50MG/100ML (0.5MG/ML) · solution;intravenous | Sodium Nitroprusside | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters